PMC5485313_01
Platelet count and romiplostim dose evolution: (a) case 1: newly diagnosed ITP; (b) case 2: persistent ITP; (c) case 3: chronic ITP; splenectomized; (d) case 4: chronic ITP; nonsplenectomized.
CRIHEM2017-4109605.001.jpg
PMC5485313_05_CRIHEM2017-4109605.001.jpg
fig1
The dose was sequentially tapered to 3 microg/Kg, to 2 microg/Kg in alternate weeks one month thereafter, and to 1 microg/Kg in alternate weeks by December 2015 (Figure 1(d)).
PMC5485313_02
Platelet count and romiplostim dose evolution: (a) case 1: newly diagnosed ITP; (b) case 2: persistent ITP; (c) case 3: chronic ITP; splenectomized; (d) case 4: chronic ITP; nonsplenectomized.
CRIHEM2017-4109605.001.jpg
PMC5485313_05_CRIHEM2017-4109605.001.jpg
fig1
The dose was sequentially tapered to 3 microg/Kg, to 2 microg/Kg in alternate weeks one month thereafter, and to 1 microg/Kg in alternate weeks by December 2015 (Figure 1(d)).
PMC5485313_03
PMC5485313_04
Platelet count and romiplostim dose evolution: (a) case 1: newly diagnosed ITP; (b) case 2: persistent ITP; (c) case 3: chronic ITP; splenectomized; (d) case 4: chronic ITP; nonsplenectomized.
CRIHEM2017-4109605.001.jpg
PMC5485313_05_CRIHEM2017-4109605.001.jpg
fig1
The dose was sequentially tapered to 3 microg/Kg, to 2 microg/Kg in alternate weeks one month thereafter, and to 1 microg/Kg in alternate weeks by December 2015 (Figure 1(d)).
PMC5485313_05
Platelet count and romiplostim dose evolution: (a) case 1: newly diagnosed ITP; (b) case 2: persistent ITP; (c) case 3: chronic ITP; splenectomized; (d) case 4: chronic ITP; nonsplenectomized.
CRIHEM2017-4109605.001.jpg
PMC5485313_05_CRIHEM2017-4109605.001.jpg
fig1
The dose was sequentially tapered to 3 microg/Kg, to 2 microg/Kg in alternate weeks one month thereafter, and to 1 microg/Kg in alternate weeks by December 2015 (Figure 1(d)).